The Experts below are selected from a list of 7686 Experts worldwide ranked by ideXlab platform
Dirk Rades - One of the best experts on this subject based on the ideXlab platform.
-
Do patients with very few Brain metastases from breast cancer benefit from Whole-Brain Radiotherapy in addition to radiosurgery?
Radiation oncology (London England), 2014Co-Authors: Dirk Rades, Stefan Huttenlocher, Dagmar Hornung, Oliver Blanck, Steven E. Schild, Dorothea FischerAbstract:Background An important issue in palliative radiation oncology is the whether Whole-Brain Radiotherapy should be added to radiosurgery when treating a limited number of Brain metastases. To optimize personalized treatment of cancer patients with Brain metastases, the value of Whole-Brain Radiotherapy should be described separately for each tumor entity. This study investigated the role of Whole-Brain Radiotherapy added to radiosurgery in breast cancer patients.
-
A survival score for patients with Brain metastases from less radiosensitive tumors treated with Whole-Brain Radiotherapy alone
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2013Co-Authors: Liesa Dziggel, Steven E. Schild, Barbara Segedin, N.h. Podvrsnik, I. Oblak, Dirk RadesAbstract:Background and purpose This study aimed to develop and validate a scoring system to predict the survival of patients receiving Whole-Brain Radiotherapy (WBRT) alone for Brain metastases from less radiosensitive tumors.
-
Validation of a survival score for patients treated with Whole-Brain Radiotherapy for Brain metastases
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2013Co-Authors: Liesa Dziggel, Steven E. Schild, Barbara Segedin, N.h. Podvrsnik, I. Oblak, Dirk RadesAbstract:Background This study was performed to validate a scoring system published in 2008 to predict the survival of patients receiving Whole-Brain Radiotherapy (WBRT) alone for Brain metastases.
-
Do patients with a limited number of Brain metastases need Whole-Brain Radiotherapy in addition to radiosurgery?
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2012Co-Authors: Dirk Rades, Steven E. SchildAbstract:Background About 40% of patients with Brain metastases have a very limited number of lesions and may be candidates for radiosurgery. Radiosurgery alone is superior to Whole-Brain Radiotherapy (WBRT) alone for control of treated and new Brain metastases. In patients with a good performance status, radiosurgery also resulted in better survival. However, the question is whether the results of radiosurgery alone can be further improved with additional WBRT.
-
Comparison of stereotactic radiosurgery (SRS) alone and Whole Brain Radiotherapy (WBRT) plus a stereotactic boost (WBRT+SRS) for one to three Brain metastases.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2008Co-Authors: Dirk Rades, Dagmar Hornung, Steven E. Schild, Jan Dirk Kueter, Theo Veninga, Patrick Hanssens, Juergen DunstAbstract:Background The best available treatment of patients with one to three Brain metastases is still unclear. This study compared the results of stereotactic radiosurgery (SRS) alone and Whole Brain Radiotherapy (WBRT) plus SRS (WBRT + SRS).
Steven E. Schild - One of the best experts on this subject based on the ideXlab platform.
-
Do patients with very few Brain metastases from breast cancer benefit from Whole-Brain Radiotherapy in addition to radiosurgery?
Radiation oncology (London England), 2014Co-Authors: Dirk Rades, Stefan Huttenlocher, Dagmar Hornung, Oliver Blanck, Steven E. Schild, Dorothea FischerAbstract:Background An important issue in palliative radiation oncology is the whether Whole-Brain Radiotherapy should be added to radiosurgery when treating a limited number of Brain metastases. To optimize personalized treatment of cancer patients with Brain metastases, the value of Whole-Brain Radiotherapy should be described separately for each tumor entity. This study investigated the role of Whole-Brain Radiotherapy added to radiosurgery in breast cancer patients.
-
A survival score for patients with Brain metastases from less radiosensitive tumors treated with Whole-Brain Radiotherapy alone
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2013Co-Authors: Liesa Dziggel, Steven E. Schild, Barbara Segedin, N.h. Podvrsnik, I. Oblak, Dirk RadesAbstract:Background and purpose This study aimed to develop and validate a scoring system to predict the survival of patients receiving Whole-Brain Radiotherapy (WBRT) alone for Brain metastases from less radiosensitive tumors.
-
Validation of a survival score for patients treated with Whole-Brain Radiotherapy for Brain metastases
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2013Co-Authors: Liesa Dziggel, Steven E. Schild, Barbara Segedin, N.h. Podvrsnik, I. Oblak, Dirk RadesAbstract:Background This study was performed to validate a scoring system published in 2008 to predict the survival of patients receiving Whole-Brain Radiotherapy (WBRT) alone for Brain metastases.
-
Do patients with a limited number of Brain metastases need Whole-Brain Radiotherapy in addition to radiosurgery?
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2012Co-Authors: Dirk Rades, Steven E. SchildAbstract:Background About 40% of patients with Brain metastases have a very limited number of lesions and may be candidates for radiosurgery. Radiosurgery alone is superior to Whole-Brain Radiotherapy (WBRT) alone for control of treated and new Brain metastases. In patients with a good performance status, radiosurgery also resulted in better survival. However, the question is whether the results of radiosurgery alone can be further improved with additional WBRT.
-
Comparison of stereotactic radiosurgery (SRS) alone and Whole Brain Radiotherapy (WBRT) plus a stereotactic boost (WBRT+SRS) for one to three Brain metastases.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2008Co-Authors: Dirk Rades, Dagmar Hornung, Steven E. Schild, Jan Dirk Kueter, Theo Veninga, Patrick Hanssens, Juergen DunstAbstract:Background The best available treatment of patients with one to three Brain metastases is still unclear. This study compared the results of stereotactic radiosurgery (SRS) alone and Whole Brain Radiotherapy (WBRT) plus SRS (WBRT + SRS).
J Dunst - One of the best experts on this subject based on the ideXlab platform.
-
comparison of stereotactic radiosurgery srs alone and Whole Brain Radiotherapy wbrt plus a stereotactic boost wbrt srs for one to three Brain metastases
Strahlentherapie Und Onkologie, 2008Co-Authors: Dirk Rades, Dagmar Hornung, Steven E. Schild, Jan Dirk Kueter, Theo Veninga, Patrick Hanssens, J DunstAbstract:Background The best available treatment of patients with one to three Brain metastases is still unclear. This study compared the results of stereotactic radiosurgery (SRS) alone and Whole Brain Radiotherapy (WBRT) plus SRS (WBRT + SRS).
-
surgical resection followed by Whole Brain Radiotherapy versus Whole Brain Radiotherapy alone for single Brain metastasis
International Journal of Radiation Oncology Biology Physics, 2008Co-Authors: Dirk Rades, Susanne Kieckebusch, Tiina Haatanen, Radka Lohynska, J Dunst, Steven E. SchildAbstract:Purpose To compare the outcome of surgical resection followed by Whole Brain Radiotherapy (WBRT) with WBRT alone in patients treated for single Brain metastasis. Methods and Materials The data from 195 patients with single Brain metastases were retrospectively evaluated. Of the 195 patients, 99 underwent resection of the metastasis followed by WBRT and 96 underwent WBRT alone. Seven additional potential prognostic factors were investigated: age, gender, Eastern Cooperative Oncology Group performance score, tumor type, interval between initial tumor diagnosis and WBRT, extracranial metastases, and recursive partitioning analysis class. Both treatment groups were well balanced for these factors. Results On multivariate analysis, improved survival was associated with resection (relative risk [RR], 1.20; 95% confidence interval [CI], 1.11–1.31; p p p = 0.002), Eastern Cooperative Oncology Group performance score of 0–1 (RR, 2.47; 95% CI, 1.70–3.59; p p p p = 0.020). Improved Brain control distant from the original site was associated with lower recursive partitioning analysis class (RR, 1.65; 95% CI, 1.03–2.69; p p = 0.016), and the absence of extracranial metastases (RR, 2.42; 95% CI, 1.52–3.88; p p p = 0.004). Conclusion In patients with a single Brain metastasis, the addition of resection to WBRT improved survival, local control at the original metastatic site, and control within the entire Brain, but did not prevent the development of new Brain metastases distant to the original site.
Jan Dirk Kueter - One of the best experts on this subject based on the ideXlab platform.
-
comparison of stereotactic radiosurgery srs alone and Whole Brain Radiotherapy wbrt plus a stereotactic boost wbrt srs for one to three Brain metastases
Strahlentherapie Und Onkologie, 2008Co-Authors: Dirk Rades, Dagmar Hornung, Steven E. Schild, Jan Dirk Kueter, Theo Veninga, Patrick Hanssens, J DunstAbstract:Background The best available treatment of patients with one to three Brain metastases is still unclear. This study compared the results of stereotactic radiosurgery (SRS) alone and Whole Brain Radiotherapy (WBRT) plus SRS (WBRT + SRS).
-
Comparison of stereotactic radiosurgery (SRS) alone and Whole Brain Radiotherapy (WBRT) plus a stereotactic boost (WBRT+SRS) for one to three Brain metastases.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2008Co-Authors: Dirk Rades, Dagmar Hornung, Steven E. Schild, Jan Dirk Kueter, Theo Veninga, Patrick Hanssens, Juergen DunstAbstract:Background The best available treatment of patients with one to three Brain metastases is still unclear. This study compared the results of stereotactic radiosurgery (SRS) alone and Whole Brain Radiotherapy (WBRT) plus SRS (WBRT + SRS).
-
A Matched-Pair Analysis Comparing Whole-Brain Radiotherapy Plus Stereotactic Radiosurgery Versus Surgery Plus Whole-Brain Radiotherapy and a Boost to the Metastatic Site for One or Two Brain Metastases
International journal of radiation oncology biology physics, 2008Co-Authors: Dirk Rades, Jan Dirk Kueter, Andre Pluemer, Theo Veninga, Steven E. SchildAbstract:Purpose To compare the results of Whole-Brain Radiotherapy plus stereotactic radiosurgery (WBRT+SRS) with those of surgery plus Whole-Brain Radiotherapy and a boost to the metastatic site (OP+WBRT+boost) for patients with one or two Brain metastases. Methods and Materials Survival, intracerebral control, and local control of the treated metastases were retrospectively evaluated. To reduce the risk of selection bias, a matched-pair analysis was performed. The outcomes of 47 patients who received WBRT+SRS were compared with those of a second cohort of 47 patients who recieved OP+WBRT+boost. The two treatment groups were matched for the following potential prognostic factors: WBRT schedule, age, gender, performance status, tumor type, number of Brain metastases, extracerebral metastases, recursive partitioning analysis class, and interval from tumor diagnosis to WBRT. Results The 1-year survival rates were 65% after WBRT+SRS and 63% after OP+WBRT+boost ( p = 0.19). The 1-year intracerebral control rates were 70% and 78% ( p = 0.39), respectively. The 1-year local control rates were 84% and 83% ( p = 0.87), respectively. On multivariate analyses, improved survival was significantly associated with better performance status ( p = 0.009), no extracerebral metastases ( p = 0.004), recursive partitioning analysis Class 1 ( p = 0.004), and interval from tumor diagnosis to WBRT ( p = 0.001). Intracerebral control was not significantly associated with any of the potential prognostic factors. Improved local control was significantly associated with no extracerebral metastases ( p = 0.037). Conclusions Treatment outcomes were not significantly different after WBRT+SRS compared with OP+WBRT+boost. However, WBRT+SRS is less invasive than OP+WBRT+boost and may be preferable for patients with one or two Brain metastases. The results should be confirmed by randomized trials.
Theo Veninga - One of the best experts on this subject based on the ideXlab platform.
-
comparison of stereotactic radiosurgery srs alone and Whole Brain Radiotherapy wbrt plus a stereotactic boost wbrt srs for one to three Brain metastases
Strahlentherapie Und Onkologie, 2008Co-Authors: Dirk Rades, Dagmar Hornung, Steven E. Schild, Jan Dirk Kueter, Theo Veninga, Patrick Hanssens, J DunstAbstract:Background The best available treatment of patients with one to three Brain metastases is still unclear. This study compared the results of stereotactic radiosurgery (SRS) alone and Whole Brain Radiotherapy (WBRT) plus SRS (WBRT + SRS).
-
Comparison of stereotactic radiosurgery (SRS) alone and Whole Brain Radiotherapy (WBRT) plus a stereotactic boost (WBRT+SRS) for one to three Brain metastases.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2008Co-Authors: Dirk Rades, Dagmar Hornung, Steven E. Schild, Jan Dirk Kueter, Theo Veninga, Patrick Hanssens, Juergen DunstAbstract:Background The best available treatment of patients with one to three Brain metastases is still unclear. This study compared the results of stereotactic radiosurgery (SRS) alone and Whole Brain Radiotherapy (WBRT) plus SRS (WBRT + SRS).
-
A Matched-Pair Analysis Comparing Whole-Brain Radiotherapy Plus Stereotactic Radiosurgery Versus Surgery Plus Whole-Brain Radiotherapy and a Boost to the Metastatic Site for One or Two Brain Metastases
International journal of radiation oncology biology physics, 2008Co-Authors: Dirk Rades, Jan Dirk Kueter, Andre Pluemer, Theo Veninga, Steven E. SchildAbstract:Purpose To compare the results of Whole-Brain Radiotherapy plus stereotactic radiosurgery (WBRT+SRS) with those of surgery plus Whole-Brain Radiotherapy and a boost to the metastatic site (OP+WBRT+boost) for patients with one or two Brain metastases. Methods and Materials Survival, intracerebral control, and local control of the treated metastases were retrospectively evaluated. To reduce the risk of selection bias, a matched-pair analysis was performed. The outcomes of 47 patients who received WBRT+SRS were compared with those of a second cohort of 47 patients who recieved OP+WBRT+boost. The two treatment groups were matched for the following potential prognostic factors: WBRT schedule, age, gender, performance status, tumor type, number of Brain metastases, extracerebral metastases, recursive partitioning analysis class, and interval from tumor diagnosis to WBRT. Results The 1-year survival rates were 65% after WBRT+SRS and 63% after OP+WBRT+boost ( p = 0.19). The 1-year intracerebral control rates were 70% and 78% ( p = 0.39), respectively. The 1-year local control rates were 84% and 83% ( p = 0.87), respectively. On multivariate analyses, improved survival was significantly associated with better performance status ( p = 0.009), no extracerebral metastases ( p = 0.004), recursive partitioning analysis Class 1 ( p = 0.004), and interval from tumor diagnosis to WBRT ( p = 0.001). Intracerebral control was not significantly associated with any of the potential prognostic factors. Improved local control was significantly associated with no extracerebral metastases ( p = 0.037). Conclusions Treatment outcomes were not significantly different after WBRT+SRS compared with OP+WBRT+boost. However, WBRT+SRS is less invasive than OP+WBRT+boost and may be preferable for patients with one or two Brain metastases. The results should be confirmed by randomized trials.
